Background: Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. As methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) have been designated as serious public threats by the CDC, the purpose of this study was to evaluate the activity of ERV and comparators against global isolates of Staphylococcus spp. and Enterococcus spp. collected from 2013-15.
Introduction
The Gram-positive organisms Staphylococcus aureus, Enterococcus spp. and coagulase-negative staphylococci are important pathogens in the hospital setting, accounting for 41% of all pathogens causing healthcare-associated infections. 1 Antibiotic resistance has increased in these organisms, and methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE) have been designated as serious public threats by the CDC. 2 Together, MRSA and VRE are leading causes of healthcareassociated infections in the US, resulting in ~12,000 deaths per year. 2, 3 Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. ERV is in phase 3 clinical development for the treatment of complicated intraabdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis.
The purpose of this study was to evaluate the activity of ERV and comparators against global isolates of Staphylococcus spp. and Enterococcus spp. collected over a three-year surveillance period (from 2013-2015) . ■ Minimal inhibitory concentration (MIC) endpoints were determined by broth microdilution according to CLSI guidelines. 4
■ Quality control testing was performed each day of testing as specifi ed by the CLSI using Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213.
■ Antibiotic susceptibility was determined using CLSI 2015 breakpoints 5 , with the exception of tigecycline where FDA breakpoints were used. 6
■ Clinical isolates were from diverse geographic locations, with 47% from countries within North America (specifi cally, the United States), 47% from within Europe, 5% from within Asia, and 1% from within the South Pacifi c (Fig. 1) .
■ Most isolates were collected from GU, respiratory, bodily fl uid and skin/ wound infection sources followed by GI and blood (Fig. 2) .
■ Tables 1 and 2 show MIC values for staphylococci and enterococci, respectively.
-ERV MIC 90 values for the organisms did not vary more than one dilution over the 3-year time range.
■ Cumulative MIC distribution patterns for MRSA and VRE organisms were similar for each of the three years, with some differences observed in the 0.015-0.06 mg/L MIC range.
■ The in vitro activity (as measured by MIC 90 values) for ERV against S. aureus, including MRSA, was up to 4-fold more potent than tigecycline and primarily 4-fold more potent than minocycline. ERV showed up to 4-fold greater activity than tigecycline, >64-fold greater activity than minocycline, and a minimum of 8-fold greater activity than vancomycin against tested enterococci, including VRE.
Results

Conclusions
■ ERV demonstrated consistent and potent in vitro activity against a global collection of Staphylococcus spp. and Enterococcus spp., including resistant strains, over a recent 3-year time period (2013) (2014) (2015) .
■ ERV shows promising activity against globally-isolated Gram-positive organisms, including those with resistant phenotypes. [2013] [2014] [2015] . The in vitro potency for ERV against these organisms was up to 4-fold greater than TGC and a minimum of 8-fold greater than VAN.
MIC 50/90 , minimum inhibitory concentration required to inhibit growth of 50/90% of isolates (mg/L); VR, vancomycin-resistant; TGC, tigecycline; VAN, vancomycin 
